This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the Version of Record. Please cite this article as doi: 10.1111/j.1365-2125.2012.04474.x
Future Pharmacological Treatments for Substance Use Disorders
© 2012 The Authors. British Journal of Clinical Pharmacology © 2012 The British Pharmacological Society
British Journal of Clinical Pharmacology
- Accepted manuscript online: 5 OCT 2012 07:25AM EST
- Manuscript Accepted: 23 SEP 2012
- Cited By
Substance use disorders represent a serious public health and social issue worldwide. Recent advances in our understanding of the neurobiological basis of the addictive processes have led to the development of a growing number of pharmacological agents to treat addictions. Despite this progress, there are no approved pharmacological treatments for cocaine, methamphetamine, and cannabis addiction. Moving treatment development to the next stage will require novel ways of approaching substance use disorders. One such novel approach is targeting individual vulnerabilities, such as cognitive function, sex differences, and psychiatric comorbidities. This review provides a summary of promising pharmacotherapies for alcohol, opiate, stimulant and nicotine addictions. Many medications that target positive and negative reinforcement of drugs, as well individual vulnerabilities to addiction are in different phases of development. Clinical trials testing the efficacy of these medications for substance use disorder are warranted.